ArticleFrontiers in cardiovascular medicine2026
Association of obesity-metabolic phenotypes with coronary artery disease prevalence: interaction and exploratory mediation analyses of high-sensitivity C-reactive protein.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the associations of obesity-metabolic phenotypes with coronary artery disease (CAD) prevalence and to evaluate the interaction between obesity and metabolic unhealthiness and the potential mediating role of high-sensitivity C-reactive protein (hsCRP). Methods: A total of 860 participants were classified as metabolically healthy non-obese (MHNO), metabolically healthy obesity (MHO), metabolically unhealthy non-obese (MUNO), or metabolically unhealthy obesity (MUO). Associations with CAD prevalence were estimated using modified Poisson regression with robust variance. Interactions between obesity and metabolic unhealthiness were assessed on multiplicative and additive scales. Subgroup and sensitivity analyses were performed, followed by an exploratory mediation analysis of hsCRP. Results: Among 860 participants, 563 (65.5%) had CAD. After adjustment for age, sex, current smoking, alcohol use, family history of CAD, lipoprotein(a) [Lp(a)], low-density lipoprotein cholesterol (LDL-C), and estimated glomerular filtration rate (eGFR), the prevalence ratios for CAD were 1.51 [95% confidence interval (CI), 1.26-1.81] for MHO, 1.73 (95% CI, 1.48-2.02) for MUNO, and 1.79 (95% CI, 1.53-2.10) for MUO compared with MHNO (all Conclusions: MHO, MUNO, and MUO were all associated with higher CAD prevalence, with stronger associations observed for metabolically unhealthy phenotypes. Obesity and metabolic unhealthiness showed a negative interaction. Exploratory findings indicated an hsCRP-related indirect association, but causal mediation cannot be inferred from this cross-sectional study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.